FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014660011> ?p ?o ?g. }

• W2014660011 endingPage "401" @default.
• W2014660011 startingPage "392" @default.
• W2014660011 abstract "Background Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy. Methods Four hundred and nine subjects from three countries with type 2 diabetes on stable insulin therapy were randomized to 26 weeks of double-blind treatment with once daily doses of 10 or 20 mg balaglitazone, 45 mg pioglitazone, or matching placebo (n ≥ 99 in each group). The primary endpoint was the efficacy of balaglitazone 10 and 20 mg versus placebo on the absolute change in haemoglobin A1c. Secondary endpoints included levels of fasting serum glucose, and changes in body composition and bone mineral density as measured by dual energy X-ray absorptiometry, in comparison to pioglitazone 45 mg. This study is registered with Clinicaltrials.gov identifier: NCT00515632. Results In the 10- and 20-mg balaglitazone groups, and in the 45-mg pioglitazone group, significant reductions in haemoglobin A1c levels were observed (−0.99, − 1.11, and − 1.22%, respectively; p < 0.0001) versus placebo. Fasting serum glucose was similarly reduced in all treatment arms. Dual energy X-ray absorptiometry analyses showed that, while balaglitazone at 10 mg caused weight gain and fluid retention compared to placebo, the magnitude of these effects was significantly smaller than that of pioglitazone 45 mg and balaglitazone 20mg. Balaglitazone at either dose did not appear to reduce bone mineral density, while Pioglitazone showed a trend towards a reduction. Conclusion Patients treated with balaglitazone at 10 mg and 20 mg and pioglitazone at 45 mg showed clinically meaningful improvements in glucose levels and HbA1c. With the 10 mg dose, the benefits (glucose & HgA1c lowering) and untoward effects (fluid and fat accumulation) were less, results that encourage further studies of this drug candidate. Copyright © 2011 John Wiley & Sons, Ltd." @default.
• W2014660011 created "2016-06-24" @default.
• W2014660011 creator A5005275771 @default.
• W2014660011 creator A5005612011 @default.
• W2014660011 creator A5005755753 @default.
• W2014660011 creator A5011776152 @default.
• W2014660011 creator A5015594299 @default.
• W2014660011 creator A5022699151 @default.
• W2014660011 creator A5062023106 @default.
• W2014660011 creator A5062465642 @default.
• W2014660011 creator A5082542112 @default.
• W2014660011 creator A5086071936 @default.
• W2014660011 creator A5090084366 @default.
• W2014660011 date "2011-05-01" @default.
• W2014660011 modified "2023-10-18" @default.
• W2014660011 title "Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy" @default.
• W2014660011 cites W1752045965 @default.
• W2014660011 cites W1968269858 @default.
• W2014660011 cites W1976956550 @default.
• W2014660011 cites W1980563065 @default.
• W2014660011 cites W1987941106 @default.
• W2014660011 cites W1990724339 @default.
• W2014660011 cites W1993888216 @default.
• W2014660011 cites W2000970191 @default.
• W2014660011 cites W2017030986 @default.
• W2014660011 cites W2055409225 @default.
• W2014660011 cites W2060678630 @default.
• W2014660011 cites W2061183108 @default.
• W2014660011 cites W2069317363 @default.
• W2014660011 cites W2070437540 @default.
• W2014660011 cites W2077151295 @default.
• W2014660011 cites W2102634320 @default.
• W2014660011 cites W2107421879 @default.
• W2014660011 cites W2114358477 @default.
• W2014660011 cites W2124533387 @default.
• W2014660011 cites W2126233607 @default.
• W2014660011 cites W2131490500 @default.
• W2014660011 cites W2131820599 @default.
• W2014660011 cites W2135729475 @default.
• W2014660011 cites W2145947168 @default.
• W2014660011 cites W2160102993 @default.
• W2014660011 cites W2171294019 @default.
• W2014660011 cites W40400977 @default.
• W2014660011 doi "https://doi.org/10.1002/dmrr.1187" @default.
• W2014660011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21328517" @default.
• W2014660011 hasPublicationYear "2011" @default.
• W2014660011 type Work @default.
• W2014660011 sameAs 2014660011 @default.
• W2014660011 citedByCount "64" @default.
• W2014660011 countsByYear W20146600112012 @default.
• W2014660011 countsByYear W20146600112013 @default.
• W2014660011 countsByYear W20146600112014 @default.
• W2014660011 countsByYear W20146600112015 @default.
• W2014660011 countsByYear W20146600112016 @default.
• W2014660011 countsByYear W20146600112017 @default.
• W2014660011 countsByYear W20146600112018 @default.
• W2014660011 countsByYear W20146600112019 @default.
• W2014660011 countsByYear W20146600112020 @default.
• W2014660011 countsByYear W20146600112021 @default.
• W2014660011 countsByYear W20146600112022 @default.
• W2014660011 countsByYear W20146600112023 @default.
• W2014660011 crossrefType "journal-article" @default.
• W2014660011 hasAuthorship W2014660011A5005275771 @default.
• W2014660011 hasAuthorship W2014660011A5005612011 @default.
• W2014660011 hasAuthorship W2014660011A5005755753 @default.
• W2014660011 hasAuthorship W2014660011A5011776152 @default.
• W2014660011 hasAuthorship W2014660011A5015594299 @default.
• W2014660011 hasAuthorship W2014660011A5022699151 @default.
• W2014660011 hasAuthorship W2014660011A5062023106 @default.
• W2014660011 hasAuthorship W2014660011A5062465642 @default.
• W2014660011 hasAuthorship W2014660011A5082542112 @default.
• W2014660011 hasAuthorship W2014660011A5086071936 @default.
• W2014660011 hasAuthorship W2014660011A5090084366 @default.
• W2014660011 hasConcept C126322002 @default.
• W2014660011 hasConcept C126894567 @default.
• W2014660011 hasConcept C134018914 @default.
• W2014660011 hasConcept C142724271 @default.
• W2014660011 hasConcept C168563851 @default.
• W2014660011 hasConcept C170493617 @default.
• W2014660011 hasConcept C203092338 @default.
• W2014660011 hasConcept C204787440 @default.
• W2014660011 hasConcept C27081682 @default.
• W2014660011 hasConcept C2776541429 @default.
• W2014660011 hasConcept C2776886416 @default.
• W2014660011 hasConcept C2777180221 @default.
• W2014660011 hasConcept C2778384471 @default.
• W2014660011 hasConcept C2778938600 @default.
• W2014660011 hasConcept C2779306644 @default.
• W2014660011 hasConcept C555293320 @default.
• W2014660011 hasConcept C58732023 @default.
• W2014660011 hasConcept C71924100 @default.
• W2014660011 hasConceptScore W2014660011C126322002 @default.
• W2014660011 hasConceptScore W2014660011C126894567 @default.
• W2014660011 hasConceptScore W2014660011C134018914 @default.
• W2014660011 hasConceptScore W2014660011C142724271 @default.
• W2014660011 hasConceptScore W2014660011C168563851 @default.
• W2014660011 hasConceptScore W2014660011C170493617 @default.
• W2014660011 hasConceptScore W2014660011C203092338 @default.

• next